All News

EULAR,poster

EULAR 2021 – Day 1 Report

Jack Cush, MD

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

Read Article
EULAR,Podcast,2021

EULAR 2021 - Day 1 Podcasts

Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 1 broadcasts below.



You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundclound.com



Listen by Clicking below:



Day 1a

Read Article
#OP0227 #TYK2 inhibitor deucravacitinib showed good efficacy in #PsA patients vs. placebo in phase 2 16weeks Primary endpoint ACR20 12mg: 62.7% 6mg: 52.9% PLC: 31.8% + well tolarated: no serious adverse events #EULAR2021 @RheumNow https://t.co/6SFqWd79db
Paul Studenic Stiddyo ( View Tweet)
Prospective analysis #OP0220 showed that PsA pt age, dz duration and activity level at tx initiation have ⬇️ with TNFi over the past 20 years. TNFi retention rates have ⬇️ while remission rates have ⬆️ (notably those in 1st yr tx) #EULAR2021 @RheumNow https://t.co/gnKRfvbHPQ https://t.co/PRunGIxMwx

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Ever wonder why one drug works in a pt & not another? Study of bio markers in PsA from RCT of #upadacitinib vs #adalimumab shows diff pathways affected by each drug & some overlap too @RheumNow #EULAR2021 @eular_org OP0030 https://t.co/WifrVOIMkW
Janet Pope Janetbirdope ( View Tweet)
UPSTREAM results #OP0223 suggest that the newly developed and preliminary validated MSKUS PsA dz activity and damage scores could be used in observational and controlled trials. #EULAR2021 @RheumNow https://t.co/Tw7OWyMcgX https://t.co/WiT0yGwVqK

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Does Guselkumab (IL23-i) modulate gene expression in #PsA? Dr Siebert analysed samples from DISCOVER RCTs & reported normalisation of⬆️regulated genes (e.g. Neutrophil,monocyte) and ⬇️regulated (B-,T- and NK cells) signatures by GUS post-therapy #EULAR2021 #POS0195 @RheumNow https://t.co/2qtpxrrwkF
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Belarus ⭐️⬇️AS activity w/ or w/o MRI sacroilitis Abs#OP0142 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

GUS causes ⬇️ in serum collagen C1M (marker of joint response), C3M, C4M, C6M. Pts achieving ACR20 at week 24 had greater C1M reduction than non-responder. Abstract #POS1036 #EULAR2021 @RheumNow https://t.co/4JqbaMexuR https://t.co/gXltKn6qIc

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & radiographic progression. Safety comparable to 6mo/1yr data, similar between Q4W & Q8W dosing, & consistent w/ PsO trials. Poster #POS1027 #EULAR2021 @RheumNow https://t.co/nlcjOX7cBq https://t.co/NWqDTwfb4u

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2021 PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate ) Dr. Rachel Tate reviews two abstracts - OP0051 and OP0049 - presented at the virtual EULAR 2021 meeting. https://t.co/sUXTXDXrFh https://t.co/tQZktnlUXj

Links:

Dr. John Cush RheumNow ( View Tweet)
#POS0196 1 year results of the SELECT-PsA 2 study: Inadequate responders to ≥1bDMARD subjected to #upadacitinib maintained efficacy throughout week 56 (74% of pts completed 1-year) #EULAR2021 @RheumNow https://t.co/xpqhzgeI6q
Paul Studenic Stiddyo ( View Tweet)
Check out our psoriatic arthritis coverage from #EULAR2021. Head to RheumNow for full EULAR coverage. https://t.co/NzB2e2Vfwb

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2021 meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

What about musculoskeletal #pain in PsO patients? Results of a nationwide Danish survey #POS0149 that shed light into unadressed reduced quality of life and risk to move towards #PsA #EULAR2021 @RheumNow https://t.co/JQnHSvtpHm

Paul Studenic Stiddyo ( View Tweet)
Data from the COSMOS study showed that 44.4% of patients who received #guselkumab versus 19.8% of patients who received placebo achieved a ≥20% improvement at week 24. #psoriaticarthritis https://t.co/S3xnFSQDaJ

Links:

Rheumatology Network RheumatologyNet ( View Tweet)

PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate) https://t.co/sUXTXDXrFh

Links:

Dr. John Cush RheumNow ( View Tweet)

An original way of differentiating RA from PsA! The shape of the second MCP in HR-pQCT is enough to train a neural network with high accuracy for recognition of -HC 94% -RA 84% -PsA 89% and an AUC of 91%. #EULAR2021 @RheumNow #OP0145 https://t.co/BrwFQpX310
Aurelie Najm AurelieRheumo ( View Tweet)
Q-DAPSA (DAPSA + CRP), validated as a clinical measure of PsA disease activity in both practice & research from 5 centers in Berlin, 104 PsA pts. Let's get more studies to better understand the power of this measure. Poster #POS1069 #EULAR2021 @RheumNow https://t.co/X4UWGwH5i5 https://t.co/J7EpOjTjhe

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
SPACING trial: possible to taper TNFi in AxSpA pts in LDA ⭐️Tapering of TNFi in axSpA resulted in 88% BASDAI<4 compared to 91.5% in unchanged group ⭐️adalimumab spaced out to q35 days Abs#OP0138 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×